Memorial Hospital Research Laboratories

The Charles Rudin Lab

Share
Print
Back to Top

Research

Charles M. Rudin, MD, PhD
Charles M. Rudin, MD, PhD


Professor

Physician-scientist Charles M. Rudin, Chief of the Thoracic Oncology Service, leads research that focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models including patient-derived xenografts. These studies are integrated with early phase clinical trials.

The Charles Rudin Lab

Featured News

MSK cancer biologist Triparna Sen
Scientists Learn More about How Lung Cancer Becomes Resistant to Drugs

Charles Rudin and Dana Pe'er
Molecular Atlas of Small Cell Lung Cancer Reveals Unusual Cell Type That Could Explain Why It’s So Aggressive

MSK cancer biologist Triparna Sen
MSK Scientists Reveal Biology of Shape-Shifting Lung Cancer

View All Featured News

Publications

Chow, A., Schad, S., Green, M., Hellmann, M.D., Allaj, V., et al. Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity. Cancer Cell (2021).

Caeser R, Hulton C, Costa E, Durani V, Little M, et. al. MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer. iScience (2021).

Chan JM, Quintanal-Villalonga Á, Gao VR, Xie Y, Allaj V, et al. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell 2021.

Quintanal-Villalonga A, Taniguchi H, Zhan YA, Hasan MM, Chavan SS, Meng F, Uddin F, et al. Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. J Hematol Oncol (2021).

Ciampricotti M, Karakousi T, Richards AL, Quintanal-Villalonga À, Karatza A, Caeser R, Costa EA, et al. Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer. Cancer Discover (2021).

View All Publications

People

Charles M. Rudin, MD, PhD

Charles M. Rudin, MD, PhD



Professor

  • Physician-scientist Charles Rudin focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models.
  • MD, PhD, University of Chicago Pritzker School of Medicine
rudinc@mskcc.org
Email Address
View physician profile
Physician profile

Members

Triparna Sen, PhD
Triparna Sen

Assistant Attending/Lab Co-Director

Nisarg Shah
Nisarg Shah

Senior Research Assistant/Lab Manager

Joseph Chan
Joseph Chan

Instructor, Thoracic Oncology Service

Andrew Chow
Andrew Chow

Assistant Attending, Thoracic Oncology Service

Emily Costa

Graduate Student

W. Victoria Lai
Victoria Lai

Assistant Attending, Thoracic Oncology Service

Hirokazu Taniguchi
Hirokazu Taniguchi

Research Fellow

Álvaro Quintanal Villalonga
Álvaro Quintanal Villalonga

Research Associate

Rebecca Caeser
Rebecca Caeser

Research Associate

Kelly Clarke
Kelly Clarke

Portfolio Manager

Vidushi Durani
Vidushi Durani

Graduate Student

Kenta Kawasaki
Kenta Kawasaki

Research Fellow

Michael Liu
Michael Liu

Research Technician

Parvathy Manoj
Parvathy Manoj

Research Technician

Evelyn Nguyen
Evelyn Nguyen

Graduate Student

Harsha Sridhar
Harsha Sridhar

Research Technician

Salomon Tendler
Salomon Tendler

Research Fellow

Kathryn M. Tully
Kathryn M. Tully

Graduate Student

Lab Alumni
Viola Allaj
Viola Allaj

Senior Research Technician

Metamia Ciampricotti
Metamia Ciampricotti

Research Fellow

John Poirier
John T. Poirier

Assistant Professor, Director, Preclinical Therapeutics Program, Perlmutter Cancer Center, NYU Langone Health

Fathema Uddin
Fathema Uddin

MD/PhD Student

Eric Gardner
Eric Gardner

Postdoctoral Research Fellow, Harold Varmus Lab, WCMC

Christopher Hulton, BS, MS
Christopher Hulton

Research Scientist at C4 Therapeutic, Watertown, Massachusetts

Corrin Wohlhieter
Corrin Wohlhieter

Senior Associate, Clarion Life Sciences

James Laird
James Laird

Medical Resident, Yale School of Medicine

Pictured: Benjamin Lok
Benjamin Lok

Clinician-Scientist, Princess Margaret Cancer Centre and Assistant Professor of Radiation Oncology, University of Toronto

Linde Miles
Linde Miles

Postdoctoral Research Fellow, Ross Levine Lab, MSKCC

Lab Affiliations

Open Positions

Career Opportunities

Apply now

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Charles M. Rudin discloses the following relationships and financial interests:

  • Amgen
    Provision of Services
  • Bridge Medicines
    Provision of Services
  • Daiichi Sankyo
    Intellectual Property Rights
  • Earli Inc.
    Ownership / Equity Interests
  • Harpoon Therapeutics, Inc.
    Provision of Services
  • Ipsen
    Provision of Services
  • Jazz Pharmaceuticals
    Provision of Services
  • Merck Sharp & Dohme
    Provision of Services
  • Pfizer, Inc.
    Provision of Services
  • Seneca Therapeutics
    Intellectual Property Rights
  • Syros
    Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures

Related topics: